Argenx SE Files December 2025 6-K Report
Ticker: ARGX · Form: 6-K · Filed: Dec 15, 2025 · CIK: 1697862
Sentiment: neutral
Topics: sec-filing, 6-k, biotech
TL;DR
ARGENX filed its monthly 6-K report on 12/15/25, standard procedure for foreign issuers.
AI Summary
Argenx SE filed a Form 6-K on December 15, 2025, reporting for the month of December 2025. The company, a biopharmaceutical firm specializing in biological products, is registered with the SEC under file number 001-38097. Its principal executive offices are located in Amsterdam, the Netherlands.
Why It Matters
This filing provides routine updates for investors and regulatory bodies regarding Argenx SE's ongoing operations and compliance as a foreign private issuer.
Risk Assessment
Risk Level: low — This filing is a routine report of a foreign private issuer and does not contain material non-public information that would typically impact risk.
Key Players & Entities
- ARGENX SE (company) — Registrant
- 001-38097 (company) — SEC File Number
- December 2025 (date) — Reporting Period
- 20251215 (date) — Filing Date
FAQ
What type of report is Argenx SE filing?
Argenx SE is filing a Form 6-K, which is a Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934.
What is the SEC file number for Argenx SE?
The SEC file number for Argenx SE is 001-38097.
For which month is this Form 6-K report being filed?
This Form 6-K report is being filed for the month of December 2025.
Where are Argenx SE's principal executive offices located?
Argenx SE's principal executive offices are located at Laarderhoogtweg 25, 1101 EB Amsterdam, the Netherlands.
What is the SIC code for Argenx SE?
The Standard Industrial Classification (SIC) code for Argenx SE is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 284 words · 1 min read · ~1 pages · Grade level 14.3 · Accepted 2025-12-15 06:15:12
Filing Documents
- tm2533481d1_6k.htm (6-K) — 12KB
- tm2533481d1_ex99-1.htm (EX-99.1) — 13KB
- 0001104659-25-120809.txt ( ) — 26KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ARGENX SE Date: December 15, 2025 By: /s/ Hemamalini (Malini) Moorthy Name: Hemamalini (Malini) Moorthy Title: General Counsel